Skip to main content
SpringerLink
Log in

History of Melanoma

  • Chapter
  • First Online:
Melanoma

Abstract

Until the mid-twentieth century, the clinical and pathological features of melanoma were not well documented, prognostic factors were poorly understood, and the evidence base for management strategies was sadly deficient. Aggressive treatment approaches for both the primary melanoma site and the regional lymph nodes had been established by the early 1900s, and continuing as the standard of care until the early 1980s. Several clinical trials failed to demonstrate a survival benefit for patients having a very wide excision of their primary melanoma, or those having elective lymph node dissection (ELND), although in two of the largest studies there was a trend in favor of ELND. In 1992, Morton et al. reported the technique of sentinel node biopsy (SNB). This identified node-positive patients most likely to benefit from a completion lymph node dissection (CLND). A large international trial, MSLT-I, showed no overall survival benefit for SNB, but did show a substantial survival benefit for SN-positive patients treated by immediate CLND compared to patients whose regional nodes were simply observed, and treated by CLND only if nodal metastases later became apparent. Initial results of a second trial initiated by Morton, MSLT-II, indicate that routine CLND in SN-positive patients confers no additional survival benefit. In the last decade, targeted inhibitors of the MAP kinase pathway and immune checkpoint inhibitors have produced remarkable improvements in the previously dismal survival outcome for patients with systemic melanoma metastases. Furthermore, the role of these agents as neoadjuvant and adjuvant therapies in high-risk patients is currently being assessed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rebecca VW, Sondak VK, Smalley KS. A brief history of melanoma: from mummies to mutations. Melanoma Res. 2012;22:114–22.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Rotte A, Bhandaru M. Melanoma—introduction, history and epidemiology. Immunotherapy of melanoma. Cham: Springer International Publishing AG; 2016. p. 3–20.

    Google Scholar 

  3. Laennec RTH. Extrait au memoire de M Laennec, sur les melanoses. Paris: Bull L’Ecole Societie de Medicine; 1812; p. 24.

    Google Scholar 

  4. Gorantla VC, Kirkwood JM. State of melanoma: an historic overview of a field in transition. Hematol Oncol Clin North Am. 2014;28:415–35.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Urteaga O, Pack GT. On the antiquity of melanoma. Cancer. 1966;19:607–10.

    Article  CAS  PubMed  Google Scholar 

  6. McGovern VJ. Melanoblastoma. Med J Aust. 1952;1:139–42.

    PubMed  CAS  Google Scholar 

  7. Paget J. Lectures on surgical pathology. In: Turner W, editor. London: Longman, Brown, Green and Longman; 1853. p. 639.

    Google Scholar 

  8. Moles and malignant melanoma: terminology and classification. Med J Aust. 1967;1:123–5.

    Google Scholar 

  9. de Vries E, Bray F, Coebergh JW, et al. Melanocytic tumours. In: PE LB, Burg G, Weedon D, Sarasin A, editors. World Health Organisation classification of tumours: pathology and genetics of skin tumours. Lyon: International Agency for Research on Cancer (IARC) Press; 2006. p. 49–120.

    Google Scholar 

  10. Clark WH Jr, From L, Bernardino EA, et al. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969;29:705–27.

    PubMed  Google Scholar 

  11. McGovern VJ. The classification of melanoma and its relationship with prognosis. Pathology. 1970;2:85–98.

    Article  CAS  PubMed  Google Scholar 

  12. Mihm MC Jr, Clark WH Jr, From L. The clinical diagnosis, classification and histogenetic concepts of the early stages of cutaneous malignant melanomas. N Engl J Med. 1971;284:1078–82.

    Article  PubMed  Google Scholar 

  13. Allen AC, Spitz S. Malignant melanoma; a clinicopathological analysis of the criteria for diagnosis and prognosis. Cancer. 1953;6:1–45.

    Article  CAS  PubMed  Google Scholar 

  14. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172:902–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Gershenwald JE, Scolyer RA, Hess KR, et al. for members of the American Joint Committee on Cancer Melanoma Expert P, the International Melanoma D, Discovery P. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67:472–492

    Google Scholar 

  16. McGovern VJ, Mihm MC Jr, Bailly C, et al. The classification of malignant melanoma and its histologic reporting. Cancer. 1973;32:1446–57.

    Article  CAS  PubMed  Google Scholar 

  17. Arrington JH 3rd, Reed RJ, Ichinose H, et al. Plantar lentiginous melanoma: a distinctive variant of human cutaneous malignant melanoma. Am J Surg Pathol. 1977;1:131–43.

    Article  PubMed  Google Scholar 

  18. McGovern VJ, Cochran AJ, Van der Esch EP, et al. The classification of malignant melanoma, its histological reporting and registration: a revision of the 1972 Sydney classification. Pathology. 1986;18:12–21.

    Article  CAS  PubMed  Google Scholar 

  19. Bahmer FA, Bahmer JA. Cutaneous melanoma—“black death” of modern times? Traces in contemporary literature. Hautarzt. 2013;64:864–7.

    Article  CAS  PubMed  Google Scholar 

  20. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma in the era of molecular profiling. Lancet. 2009;374:362–5.

    Article  PubMed  Google Scholar 

  21. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135–47.

    Article  CAS  PubMed  Google Scholar 

  22. Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell. 2015;161:1681–96.

    Google Scholar 

  23. Norris W. Eight cases of melanosis with pathological and therapeutic remarks on that disease. London: Longman and Robarts; 1857.

    Google Scholar 

  24. Norris W. Case of fungoid disease. Edinburgh Med Surg J. 1820;16:562–5.

    Google Scholar 

  25. Begg CB, Orlow I, Hummer AJ, et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst. 2005;97:1507–15.

    Article  CAS  PubMed  Google Scholar 

  26. Pemberton O. On melanosis. Observations on the history, pathology and treatment of cancerous disease. London: John Churchill; 1858. p. 1–38.

    Google Scholar 

  27. Davis NC, Shaw HM, McCarthy WH. Melanoma: an historical perspective. In: Thompson JF, Morton DL, Kroon BBR, editors. Textbook of melanoma. London, UK: Martin Dunitz; 2004. p. 1–12.

    Google Scholar 

  28. Randle HW. Suntanning: differences in perceptions throughout history. Mayo Clin Proc. 1997;72:461–6.

    Article  CAS  PubMed  Google Scholar 

  29. Lancaster HO. Some geographical aspects of the mortality from melanoma in Europeans. Med J Aust. 1956;43:1082–7.

    PubMed  CAS  Google Scholar 

  30. Cooper AGS. The contribution of radiotherapy to the problem of skin cancer in Queensland. Acta Radiol Suppl. 1959;188:61–70.

    PubMed  CAS  Google Scholar 

  31. Sarnat BG, Schour I. Oral and facial cancer. Chicago: The Yearbook Publishers, Inc.; 1950.

    Google Scholar 

  32. Lancaster HO, Nelson J. Sunlight as a cause of melanoma; a clinical survey. Med J Aust. 1957;44:452–6.

    PubMed  CAS  Google Scholar 

  33. Cooper S. The first lines of the theory and practice of surgery. London: Longman; 1840.

    Google Scholar 

  34. Home E. Observations on cancer, connected with histories of the disease. London: W. Bulmer and Co.; 1805.

    Google Scholar 

  35. Bodenham DC. A study of 650 observed malignant melanomas in the south-west region. Ann R Coll Surg Engl. 1968;43:218–39.

    PubMed  PubMed Central  CAS  Google Scholar 

  36. Fergusson A. Recurrence of a melanotic tumour: removal. Lancet. 1851;57:622.

    Article  Google Scholar 

  37. McCarthy WH, Shaw HM. The surgical treatment of primary melanoma. Hematol Oncol Clin North Am. 1998;12:797–805. 

    Article  CAS  PubMed  Google Scholar 

  38. Snow H. Melanotic cancerous disease. Lancet. 1892;140:872–4.

    Article  Google Scholar 

  39. Eve F. A lecture on melanoma. Practitioner. 1903;70:165–74.

    Google Scholar 

  40. Handley WS. The pathology of melanotic growths in relation to their operative treatment. Lancet. 1907;169:927–33.

    Article  Google Scholar 

  41. Pringle JH. A method of operation in melanotic tumours of the skin. Edinb Med J. 1908;23:496–9.

    PubMed Central  Google Scholar 

  42. Balch CM, Soong S, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol. 2000;7:87–97.

    Article  CAS  PubMed  Google Scholar 

  43. Cascinelli N, Morabito A, Santinami M, et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet. 1998;351:793–6.

    Article  CAS  PubMed  Google Scholar 

  44. Röntgen WC, Stokes GGB, Thomson JJ. Röntgen rays—memoirs by Röntgen, Stokes and JJ Thomson. New York and London: Harper & Brothers Publishers; 1899.

    Google Scholar 

  45. Becquerel H. Sur les radiations émises par phosphorescence. C R Acad Sci. 1896;122:420–1.

    CAS  Google Scholar 

  46. Curie P, Curie M, Bémont MG. Sur une nouvelle substance fortement redio-active, contenue dans la pecheblende. C R Acad Sci. 1898;127:1215–7.

    CAS  Google Scholar 

  47. Coutard H. The results and methods of treatment of cancer by radiation. Ann Surg. 1937;106:584–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Dewey DL. The radiosensitivity of melanoma cells in culture. Br J Radiol. 1971;44:816–7.

    Article  CAS  PubMed  Google Scholar 

  49. Barranco SC, Romsdahl MM, Humphrey RM. The radiation response of human malignant melanoma cells grown in vitro. Cancer Res. 1971;31:830–3.

    PubMed  CAS  Google Scholar 

  50. Johanson CR, Harwood AR, Cummings BJ, et al. 0-7-21 radiotherapy in nodular melanoma. Cancer. 1983;51:226–32.

    Article  CAS  PubMed  Google Scholar 

  51. Burmeister BH, Henderson MA, Ainslie J, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol. 2012;13:589–97.

    Article  PubMed  Google Scholar 

  52. Overgaard J, Gonzalez Gonzalez D, Hulshof MC, et al. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. Int J Hyperth. 1996;12:3–20.

    Article  CAS  Google Scholar 

  53. Larsson BS, Larsson B, Roberto A. Boron neutron capture therapy for malignant melanoma: an experimental approach. Pigment Cell Res. 1989;2:356–60.

    Article  CAS  PubMed  Google Scholar 

  54. Raja C, Graham P, Abbas Rizvi SM, et al. Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma. Cancer Biol Ther. 2007;6:846–52.

    Article  CAS  PubMed  Google Scholar 

  55. Lawton AW. Proton beam therapy for uveal melanoma. Ophthalmology. 1989;96:138–9.

    Article  CAS  PubMed  Google Scholar 

  56. Marucci L, Ancukiewicz M, Lane AM, et al. Uveal melanoma recurrence after fractionated proton beam therapy: comparison of survival in patients treated with reirradiation or with enucleation. Int J Radiat Oncol Biol Phys. 2011;79:842–6.

    Article  PubMed  Google Scholar 

  57. Yaeh A, Nanda T, Jani A, et al. Control of brain metastases from radioresistant tumors treated by stereotactic radiosurgery. J Neuro-Oncol. 2015;124:507–14.

    Article  CAS  Google Scholar 

  58. Okwan-Duodu D, Pollack BP, Lawson D, et al. Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma. Am J Clin Oncol. 2015;38:119–25.

    Article  CAS  PubMed  Google Scholar 

  59. Creech O Jr, Krementz ET, Ryan RF, et al. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148:616–32.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Kapma MR, Vrouenraets BC, Nieweg OE, et al. Major amputation for intractable extremity melanoma after failure of isolated limb perfusion. Eur J Surg Oncol. 2005;31:95–9.

    Article  CAS  PubMed  Google Scholar 

  61. Thompson JF, Waugh RC, Saw RPM, et al. Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Regional Cancer Treatment. 1994;7:188–92.

    Google Scholar 

  62. Kroon HM, Coventry BJ, Giles MH, et al. Australian multicenter study of isolated limb infusion for melanoma. Ann Surg Oncol. 2016;23:1096–103.

    Article  PubMed  Google Scholar 

  63. Coley WB. The therapeutic value of the mixed toxins of the streptococcus of erysipelas and bacillus prodigiosus in the treatment of inoperable malignant tumors. With a report of 160 cases. Am J Med Sci. 1896;112:251–81.

    Article  Google Scholar 

  64. Nathanson L, Schoenfeld D, Regelson W, et al. Prospective comparison of intralesional and multipuncture BCG in recurrent intradermal melanoma. Cancer. 1979;43:1630–5.

    Article  CAS  PubMed  Google Scholar 

  65. Krown SE, Hilal EY, Pinsky CM, et al. Intralesional injection of the methanol extraction residue of bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma. Cancer. 1978;42:2648–60.

    Article  CAS  PubMed  Google Scholar 

  66. Mastrangelo MJ, Sulit HL, Prehn LM, et al. Intralesional BCG in the treatment of metastatic malignant melanoma. Cancer. 1976;37:684–92.

    Article  CAS  PubMed  Google Scholar 

  67. Oratz R, Hauschild A, Sebastian G, et al. Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma. Melanoma Res. 2003;13:59–66.

    Article  CAS  PubMed  Google Scholar 

  68. Adler A, Stein JA, Kedar E, et al. Intralesional injection of interleukin-2-expanded autologous lymphocytes in melanoma and breast cancer patients: a pilot study. J Biol Response Mod. 1984;3:491–500.

    PubMed  CAS  Google Scholar 

  69. Thompson JF, Hersey P, Wachter E. Chemoablation of metastatic melanoma using intralesional rose Bengal. Melanoma Res. 2008;18:405–11.

    Article  PubMed  Google Scholar 

  70. Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780–8.

    Article  CAS  PubMed  Google Scholar 

  71. Allen BJ, Raja C, Rizvi S, et al. Intralesional targeted alpha therapy for metastatic melanoma. Role of electrochemotherapy in the treatment of metastatic melanoma and other metastatic and primary skin tumors [Review]. Cancer Biol Ther. 2006;5:118–9.

    Article  Google Scholar 

  72. Byrne CM, Thompson JF, Johnston H, et al. Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res. 2005;15:45–51.

    Article  CAS  PubMed  Google Scholar 

  73. Campana LG, Testori A, Mozzillo N, et al. Treatment of metastatic melanoma with electrochemotherapy. J Surg Oncol. 2014;109:301–7.

    Article  CAS  PubMed  Google Scholar 

  74. Dolinsek T, Prosen L, Cemazar M, et al. Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors. Radiol Oncol. 2016;50:274–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Kunte C, Letule V, Gehl J, et al. Electrochemotherapy in the treatment of metastatic malignant melanoma: a prospective cohort study by InspECT. Br J Dermatol. 2017;176(6):1475–85.

    Article  CAS  PubMed  Google Scholar 

  76. Okino M, Mohri H. Effects of a high-voltage electrical impulse and an anticancer drug on in vivo growing tumors. Jpn J Cancer Res. 1987;78:1319–21.

    PubMed  CAS  Google Scholar 

  77. Damian DL, Thompson JF. Treatment of extensive cutaneous metastatic melanoma with topical diphencyprone. J Am Acad Dermatol. 2007;56:869–71.

    Article  PubMed  Google Scholar 

  78. Delamere G, Poirier P, Charpy A. The lymphatics: general anatomy of the Lymphatics, with special study of the Lymphatics in different parts of the body. Westminster: Archibald Constable & Co. Ltd; 1903.

    Google Scholar 

  79. Bartholin T. De lacteis thoracicis in homine brutisque nuperrime observatis, historia anatomica. Martzan, M: Copenhagen, Denmark; 1652.

    Google Scholar 

  80. Nieweg OE, Uren RF, Thompson JF. The history of sentinel lymph node biopsy. Cancer J. 2015;21:3–6.

    Article  PubMed  Google Scholar 

  81. Virchow R. Die Krankhaften Geschwulste. Berlin, Germany: Hirschwald; 1863.

    Google Scholar 

  82. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392–9.

    Article  CAS  PubMed  Google Scholar 

  83. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–17.

    Article  CAS  PubMed  Google Scholar 

  84. Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599–609.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Faries MB, Thompson JF, Cochran AJ, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med. 2017;376:2211–2222.

    Google Scholar 

  86. Thompson JF, Uren RF, Shaw HM, et al. Location of sentinel lymph nodes in patients with cutaneous melanoma: new insights into lymphatic anatomy. J Am Coll Surg. 1999;189:195–204.

    Article  CAS  PubMed  Google Scholar 

  87. Uren RF, Howman-Giles RB, Shaw HM, et al. Lymphoscintigraphy in high-risk melanoma of the trunk: predicting draining node groups, defining lymphatic channels and locating the sentinel node. J Nucl Med. 1993;34:1435–40.

    PubMed  CAS  Google Scholar 

  88. Hill GJ 2nd, Krementz ET, Hill HZ. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer. 1984;53:1299–305.

    Article  PubMed  Google Scholar 

  89. Coates AS, Segelov E. Long term response to chemotherapy in patients with visceral metastatic melanoma. Ann Oncol. 1994;5:249–51.

    Article  CAS  PubMed  Google Scholar 

  90. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105–16.

    Article  CAS  PubMed  Google Scholar 

  92. Atkins MB, Hsu J, Lee S, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the eastern cooperative oncology group. J Clin Oncol. 2008;26:5748–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Flaherty KT, Lee SJ, Zhao F, et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol. 2013;31:373–9.

    Article  CAS  PubMed  Google Scholar 

  94. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012;379:1893–901.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107–14.

    Article  CAS  PubMed  Google Scholar 

  98. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of Ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Lee J, Kefford R, Carlino M. PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges. Immunotherapy. 2016;8:733–46.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia

    John F. Thompson M.D., Richard Kefford & Richard Scolyer

  2. Sydney Medical School, The University of Sydney, Sydney, NSW, Australia

    John F. Thompson M.D. & Richard Scolyer

  3. Royal Prince Alfred Hospital, Camperdown, NSW, Australia

    John F. Thompson M.D. & Richard Scolyer

  4. Faculty of Medicine and Health Sciences, Macquarie University, North Ryde, NSW, Australia

    John F. Thompson M.D.

  5. Westmead Hospital, Westmead, NSW, Australia

    Richard Kefford

  6. Western Sydney University, Bathurst Clinical School, Bathurst, NSW, Australia

    Graham Stevens

  7. Orange Hospital, Orange, NSW, Australia

    Graham Stevens

Authors
  1. John F. Thompson M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard Kefford
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Graham Stevens
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Richard Scolyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John F. Thompson M.D. .

Editor information

Editors and Affiliations

  1. Louisiana State University, New Orleans, Louisiana, USA

    Adam I. Riker

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Thompson, J.F., Kefford, R., Stevens, G., Scolyer, R. (2018). History of Melanoma. In: Riker, A. (eds) Melanoma. Springer, Cham. https://doi.org/10.1007/978-3-319-78310-9_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-78310-9_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-78309-3

  • Online ISBN: 978-3-319-78310-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation